Zoonotic H5N1 Avian Flu Resurgence in Cambodia
“`html
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Understanding RSV and why It’s a Threat to Seniors
Respiratory Syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. though, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization.Before the advancement of a vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the United States.
The virus spreads through close contact with infected individuals, often via respiratory droplets produced during coughing or sneezing. Older adults are notably vulnerable due to age-related decline in immune function and the presence of underlying health conditions like heart disease and chronic obstructive pulmonary disease (COPD).
The Arexvy Vaccine: Trial results and Efficacy
The approval of Arexvy,manufactured by GSK,is based on data from the Phase 3 RSV vaccine trial published in the New England Journal of Medicine on October 23,2025. The trial, involving nearly 25,000 adults aged 60 years and older, demonstrated significant efficacy in preventing RSV-associated lower respiratory tract disease (RSV-LRTD).
Key findings from the trial include:
- Overall Efficacy: Arexvy showed an overall vaccine efficacy of 82.6% against RSV-LRTD.
- Severe Illness: The vaccine demonstrated 94.1% efficacy against severe RSV-LRTD, defined as illness requiring hospitalization.
- Hospitalization: Arexvy reduced RSV-related hospitalizations by 65.2%.
- Serious Adverse Events: Serious adverse events were rare and not substantially different between the vaccine and placebo groups. The most common side effects were local reactions at the injection site, such as pain, redness, and swelling, and systemic reactions like fatigue and muscle aches.
Who should Get the RSV Vaccine?
The FDA approved Arexvy for adults aged 60 years and older. The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) will provide further recommendations regarding specific populations who should prioritize vaccination. currently, the CDC recommends a shared clinical decision-making approach, meaning individuals should discuss the benefits and risks of vaccination with their healthcare provider.
Factors to consider when deciding whether to get vaccinated include:
- Age
- Underlying health conditions
- Risk of exposure to RSV
- Individual preferences
Potential Side Effects and Safety Concerns
As with any vaccine, Arexvy can cause side effects. The most common side effects reported in clinical trials were mild